Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting

References

• Kim A, Ueda Y, Naka T, et al. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14.
   PubMed Web of Science ®Google Scholar
• Lu Z, Wang J, Wientjes MG, et al. Intraperitoneal therapy for peritoneal cancer. Future Oncol. 2010;6(10):1625–1641.
   PubMed Web of Science ®Google Scholar
• Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;(1):CD005340.
   PubMed Web of Science ®Google Scholar
• Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist. 2009;14(7):683–694.
   PubMed Web of Science ®Google Scholar
• Ansaloni L, Agnoletti V, Amadori A, et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22(5):778–785.
   PubMed Web of Science ®Google Scholar
• Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
   PubMed Web of Science ®Google Scholar
• Song CW. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res. 1984;44(10 Suppl):4721s–4730s.
   PubMed Web of Science ®Google Scholar
• Engin K. Biological rationale for hyperthermia in cancer treatment (II). Neoplasma. 1994;41(5):277–283.
   PubMed Web of Science ®Google Scholar
• de Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res. 2007;169:39–51.
   PubMedGoogle Scholar
• Rettenmaier MA, Mendivil AA, Gray CM, et al. Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma. Int J Hyperthermia. 2015;31(4):396–402.
   PubMed Web of Science ®Google Scholar
• Li GC, Mivechi NF, Weitzel G. Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Int J Hyperthermia. 1995;11(4):459–488.
   PubMed Web of Science ®Google Scholar
• Rylander MN, Feng Y, Bass J, et al. Thermally induced injury and heat-shock protein expression in cells and tissues. Ann N Y Acad Sci. 2005;1066:222–242.
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–284.
   PubMed Web of Science ®Google Scholar
• Steg AD, Bevis KS, Katre AA, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res. 2012;18(3):869–881.
   PubMed Web of Science ®Google Scholar
• Ma S, Lee TK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27(12):1749–1758.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315–1321.
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313–323.
   PubMed Web of Science ®Google Scholar
• Fagotti A, Costantini B, Vizzielli G, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122(2):221–225.
   PubMed Web of Science ®Google Scholar
• Costales AB, Chambers L, Chichura A, et al. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer. J Gynecol Obstet Hum Reprod. 2021;50(5):101844.
   PubMed Web of Science ®Google Scholar
• Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012;2012:608406.
   PubMedGoogle Scholar
• Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med. 2016;94(5):509–522.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231–237.
   PubMed Web of Science ®Google Scholar
• Hart KM, Byrne KT, Molloy MJ, et al. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol. 2011;2:29.
   PubMed Web of Science ®Google Scholar
• Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–119.
   PubMed Web of Science ®Google Scholar
• Frey B, Weiss EM, Rubner Y, et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia. 2012;28(6):528–542.
   PubMed Web of Science ®Google Scholar
• Huang W-C, Wu C-C, Hsu Y-T, et al. Effect of hyperthermia on improving neutrophil restoration after intraperitoneal chemotherapy. Int J Hyperthermia. 2019;36(1):1254–1262.
   Web of Science ®Google Scholar
• Chang C-L, Wu C-C, Hsu Y-T, et al. Immune vulnerability of ovarian cancer stem-like cells due to low CD47 expression is protected by surrounding bulk tumor cells. Oncoimmunology. 2020;9(1):1803530.
   PubMed Web of Science ®Google Scholar
• Curley MD, Therrien VA, Cummings CL, Sergent PA, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27(12):2875–2883.
   PubMed Web of Science ®Google Scholar
• Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44(1):240–251.
   PubMed Web of Science ®Google Scholar
• Kumar D, Kumar S, Gorain M, et al. Notch1-MAPK signaling axis regulates CD133+ cancer stem cell-mediated melanoma growth and angiogenesis. J Invest Dermatol. 2016;136(12):2462–2474.
   PubMed Web of Science ®Google Scholar
• Xiang D, Shigdar S, Bean AG, et al. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. Theranostics. 2017;7(17):4071–4086.
   PubMed Web of Science ®Google Scholar
• Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–179.
   PubMed Web of Science ®Google Scholar
• Yoshimatsu K, Kuhara K, Itagaki H, et al. Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer. Anticancer Res. 2008;28(1B):373–378.
   PubMed Web of Science ®Google Scholar
• Guardiola E, Delroeux D, Heyd B, et al. Pivot X: Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol. 2009;7:14.
   PubMed Web of Science ®Google Scholar
• Murshid A, Gong J, Calderwood SK. The role of heat shock proteins in antigen cross presentation. Front Immunol. 2012;3:63.
   PubMed Web of Science ®Google Scholar
• Calderwood SK, Stevenson MA, Murshid A. Heat shock proteins, autoimmunity, and cancer treatment. Autoimmune Dis. 2012;2012:486069.
   PubMedGoogle Scholar
• Zhou YJ, Binder RJ. The heat shock protein-CD91 pathway mediates tumor immunosurveillance. Oncoimmunology. 2014;3(4):e28222.
   PubMed Web of Science ®Google Scholar
• Burke AR, Singh RN, Carroll DL, et al. The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials. 2012;33(10):2961–2970.
   PubMed Web of Science ®Google Scholar
• Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12(3):689–701.
   PubMedGoogle Scholar
• Li L, ten Hagen TL, Bolkestein M, et al. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release. 2013;167(2):130–137.
   PubMed Web of Science ®Google Scholar
• van Rhoon GC, Franckena M, Ten Hagen TLM. A moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy. Adv Drug Deliv Rev. 2020;163–164:145–156.
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699–713.
   PubMed Web of Science ®Google Scholar
• Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2(63):63ra94.
   PubMed Web of Science ®Google Scholar
• Boussios S, Sadauskaite A, Kanellos FS, Tsiouris AK, et al. Neoadjuvant, HIPEC and maintenance treatment in ovarian and peritoneal serous cancer: current status. Gynecol Pelvic Med. 2020;3:19–19.
   Google Scholar
• Yagawa Y, Tanigawa K, Kobayashi Y, et al. Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery. JCMT. 2017;3(10):218–230.
   Google Scholar